EUVIMEDEUVIMED entdecken
Crossref

Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers

Chenyan Sun, Huacheng Luo, Jing Zhang

RNA · 2026-09 · 32 (9) · 1345-1354

DOI: 10.1261/rna.081080.126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift RNA, online erschienen am 17.06.2026. Verfasst von Chenyan Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China. Hauptthemen laut MEDLINE: Alternative Splicing, Protein Kinase Inhibitors, Cell Cycle Proteins, Breast Neoplasms. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in BRCA1 are key drivers of breast cancer by impairing homologous recombination. While these tumors are often sensitive to PARP inhibitors, resistance frequently emerges, highlighting the need to identify additional molecular vulnerabilities. HORMAD1 is frequently overexpressed in triple-negative breast cancer and associated with genomic instability, yet its role in therapy response in BRCA1-deficient tumors remains unclear. Here, transcriptomic profiling of BRCA1-mutant breast cancer identified HORMAD1 as one of the most upregulated and alternatively spliced genes. The splicing inhibitor isoginkgetin globally altered alternative splicing patterns in BRCA1-mutant cells, promoting HORMAD1 exon 4 inclusion. We found that RNA-binding protein RBM38 is correlated with exon 4 inclusion, and RBM38 knockdown further sensitized BRCA1-mutant cells to MEK1 inhibition. Together, these findings define an RBM38-HORMAD1 signaling as a potential therapeutic vulnerability in BRCA1-mutant breast cancer and suggest that targeting splicing regulation may represent a promising strategy to enhance treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alternative SplicingProtein Kinase InhibitorsCell Cycle ProteinsBreast NeoplasmsHumansFemaleRNA-Binding ProteinsBRCA1 ProteinGene Expression Regulation, NeoplasticCell Line, TumorMutationDrug Resistance, NeoplasmRNA SplicingTriple Negative Breast Neoplasms

Stichwörter der Autor:innen

BRCA1HORMAD1MEK inhibitorRBM38alternative splicing

Substanzen

RNA-Binding ProteinsProtein Kinase InhibitorsBRCA1 ProteinCell Cycle ProteinsBRCA1 protein, human

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
  • College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China zhangjing@him.cas.cn.

Zitieren

APA

Sun, C., Luo, H., & Zhang, J. (2026). Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers. RNA, 32(9), 1345-1354. https://doi.org/10.1261/rna.081080.126

Vancouver

Sun C, Luo H, Zhang J. Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers. RNA. 2026;32(9):1345-1354. doi:10.1261/rna.081080.126

BibTeX
@article{Sun2026,
  author = {Sun, Chenyan and Luo, Huacheng and Zhang, Jing},
  title = {Targeting HORMAD1 splicing enhances MEK inhibitor sensitivity in breast cancers},
  journal = {RNA},
  year = {2026},
  volume = {32},
  number = {9},
  pages = {1345--1354},
  doi = {10.1261/rna.081080.126}
}
Kostenlos starten →